우바우르시
Uva Ursi
📚 관련 논문 (21편)
1. Clin Microbiol Infect. 2021 Oct;27(10):1441-1447. doi: 10.1016/j.cmi.2021.05.032. Epub 2021 Jun 7. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Gágyor I(1), Hummers E(2), Schmieman
2. Food Chem Toxicol. 2018 Oct;120:651-661. doi: 10.1016/j.fct.2018.07.058. Epub 2018 Jul 31. Identification and characterization of in vitro inhibitors against UDP-glucuronosyltransferase 1A1 in uva-ursi extracts and evaluation of in vivo uva-ursi-drug interactions. Park JB(1), Kim D(1), Min J
3. Am J Nephrol. 2014;40(5):393-8. doi: 10.1159/000368724. Epub 2014 Nov 6. Internet claims on dietary and herbal supplements in advanced nephropathy: truth or myth. Vamenta-Morris H(1), Dreisbach A, Shoemaker-Moyle M, Abdel-Rahman EM. Author information: (1)University of Virginia Health System,
4. Microbiol Res. 2014 Apr;169(4):307-13. doi: 10.1016/j.micres.2013.06.013. Epub 2013 Jul 31. Medicinal plant extracts variously modulate susceptibility of Escherichia coli to different antibiotics. Samoilova Z(1), Smirnova G(1), Muzyka N(1), Oktyabrsky O(2). Author information: (1)Institute o
5. Antimicrob Agents Chemother. 2001 Nov;45(11):3198-201. doi: 10.1128/AAC.45.11.3198-3201.2001. Marked potentiation of activity of beta-lactams against methicillin-resistant Staphylococcus aureus by corilagin. Shimizu M(1), Shiota S, Mizushima T, Ito H, Hatano T, Yoshida T, Tsuchiya T. Author
6. Yakugaku Zasshi. 1992 Sep;112(9):673-7. doi: 10.1248/yakushi1947.112.9_673. [Pharmacological studies on leaf of Arctostaphylos uva-ursi (L.) Spreng. V. Effect of water extract from Arctostaphylos uva-ursi (L.) Spreng. (bearberry leaf) on the antiallergic and antiinflammatory activities of dexa
7. Yakugaku Zasshi. 1991 Apr-May;111(4-5):253-8. doi: 10.1248/yakushi1947.111.4-5_253. [Pharmacological studies on leaf of Arctostaphylos uva-ursi (L.) Spreng. III. Combined effect of arbutin and indomethacin on immuno-inflammation]. [Article in Japanese] Matsuda H(1), Tanaka T, Kubo M. Author
8. Cochrane Database Syst Rev. 2024 Dec 19;12(12):CD014762. doi: 10.1002/14651858.CD014762.pub2. Non-steroidal anti-inflammatory drugs for treating symptomatic uncomplicated urinary tract infections in non-pregnant adult women. Sachdeva A(1)(2), Rai BP(3), Veeratterapillay R(3), Harding C(3), Na
1. BMJ Open. 2022 Jun 24;12(6):e057982. doi: 10.1136/bmjopen-2021-057982. Bearberry in the treatment of acute uncomplicated cystitis (BRUMI): protocol of a multicentre, randomised double-blind clinical trial. Tóth B(#)(1), Jávorházy A(#)(2), Nyirády P(3), Csupor-Löffler B(4), Birinyi P(5), Zhanel G(6), Naber K(7), Länger R(8), Vörhendi N(4), Gede N(4), Váncsa S(9)(10), Hegyi P(4)(9)(10), Csupor D(11)(4)(12). Author information: (1)Department of Pharmacognosy, University of Szeged, Szeged, Hungary. (2)Urology Clinic, Medical School, University of Pécs, Pécs, Hungary. (3)Department of Urology, Faculty of Medicine, Semmelweis University, Budapest, Hungary. (4)Institute for Translational Medicine, Szentágothai Research Centre, Medical School, University of Pécs, Pécs, Hungary. (5)Department of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, Budapest, Hungary. (6)Departmental of Medical Microbiology/Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada. (7)Department of Urology, Technical University of Munich, Munich, Germany. (8)Austrian Medicines and Medical Devices Agency, Vienna, Austria. (9)Centre for Translational Medicine, Semmelweis University, Budapest, Hungary. (10)Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary. (11)Department of Pharmacognosy, University of Szeged, Szeged, Hungary csupor.dezso@szte.hu. (12)Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary. (#)Contributed equally BACKGROUND: Bearberry (Arctostaphylos uva-ursi) leaf is available as a treatment of uncomplicated cystitis in several European countries. The antimicrobial activity of its extracts and some of its individual constituents has been observed in vitro; however, the efficacy of bearberry compared with standard antimicrobial therapy has not been assessed yet. OBJECTIVE: The objective of the study is to assess the safety and non-inferiority of bearberry as an alternative therapy in the treatment of acute uncomplicated cystitis in comparison with standard antibiotic therapy (fosfomycin). METHODS AND ANALYSIS: This is a randomised controlled double-blinded multicentre trial. Eligible patients will be premenopausal women with a sum score of ≥6 for the typical acute uncomplicated cystitis symptoms (frequency, urgency, painful urination, incomplete emptying, suprapubic pain and visible haematuria) reported on the Acute Cystitis Symptom Score (ACSS) typical domain and pyuria. Patients will be randomly assigned to receive 3 g single dose of fosfomycin powder and two placebo tablets three times a day for 7 days or B a single dose of placebo powder and two tablets containing a dry extract of Uvae ursi folium. At least 504 patients (allocated as 1:1) will need to be enrolled to access non-inferiority with a non-inferiority limit of 14% for the primary endpoint.Improvement of symptoms of uncomplicated cystitis (based on the ACSS score) at day 7 is defined as the primary endpoint, whereas several secondary endpoints such as the number and ratio of patients with bacteriuria at day 7, frequency and severity of side effects; recurrence of urinary tract infection, concurrent use of other over the counter (OTC) medications and food supplements will be determined to elucidate more detailed differences between the groups. The number of recurrences and medications taken for treatment will be monitored for a follow-up period of 90 days (80-100 days). ETHICS AND DISSEMINATION: This study has been approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (IV/4225-1/2021/EKU). The results will be disseminated by publication of peer-reviewed manuscripts. TRIAL REGISTRATION NUMBER: NCT05055544. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. DOI: 10.1136/bmjopen-2021-057982 PMCID: PMC9234905 PMID: 35750460 [Indexed for MEDLINE] Conflict of interest statement: Competing interests: None declared.
2. J Diabetes. 2016 Sep;8(5):647-56. doi: 10.1111/1753-0407.12342. Epub 2015 Dec 1. Controlling type 2 diabetes mellitus with herbal medicines: A triple-blind randomized clinical trial of efficacy and safety. Mirfeizi M(1), Mehdizadeh Tourzani Z(2), Mirfeizi SZ(3), Asghari Jafarabadi M(4), Rezvani HR(1), Afzali M(5). Author information: (1)Department of Midwifery, College of Nursing & Midwifery, Karaj Branch, Islamic Azad University, Alborz, Iran. (2)Department of Midwifery, Alborz University of Medical Sciences, Alborz, Iran. (3)Rheumatic Diseases Research Center, Department of Rheumatology, Mashhad University of Medical Sciences, Mashhad, Iran. (4)Tabriz Health Services Management Research Center, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran. (5)Department of Pharmacoeconomy and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. BACKGROUND: The use of alternative medicines is common in patients with diabetes mellitus. The primary aim of the present study was to determine the effects of cinnamon and Caucasian whortleberry (Vaccinium arctostaphylos L.) on blood glucose control, lipid profile and body mass index (BMI) in patients with type 2 diabetes (T2DM). METHODS: In all, 105 T2DM patients were recruited to the present randomized triple-blinded clinical trial. Patients were randomly divided into three groups and administered either placebo, cinnamon or whortleberry supplements (1 g/day) for 90 days. Fasting blood glucose (FBG), serum insulin, lipid profiles, and HbA1c were measured before and after the study. RESULTS: There were no significant differences in baseline characteristics among the three groups. After treatment, FBG, 2-h blood postprandial glucose and homeostasis model assessment of insulin resistance (HOMA-IR) scores were significantly reduced in patients in the whortleberry group, but not in the placebo group. After treatment, there was a significant difference in BMI between the cinnamon and control groups (P = 0.02). There were no significant differences in any variables between the cinnamon and whortleberry groups (P>0.05 for all). In addition, there was a significant decrease in all indices of glucose control in all the cinnamon and whortleberry groups (P < 0.05). CONCLUSIONS: There were no significant differences in blood glucose levels, insulin sensitivity or lipid profile among the three groups. However, the use of cinnamon and whortleberry in addition to conventional medical treatment is recommended to adjust weight and blood glucose levels in patients with T2DM, respectively. © 2015 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd. DOI: 10.1111/1753-0407.12342 PMID: 26362826 [Indexed for MEDLINE]
3. Evid Based Complement Alternat Med. 2014;2014:217451. doi: 10.1155/2014/217451. Epub 2014 Jan 23. Evaluation of the Effects of Vaccinium arctostaphylos L. Fruit Extract on Serum Lipids and hs-CRP Levels and Oxidative Stress in Adult Patients with Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Soltani R(1), Hakimi M(1), Asgary S(2), Ghanadian SM(3), Keshvari M(2), Sarrafzadegan N(2). Author information: (1)Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. (2)Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. (3)Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. Background. Dyslipidemia produces atherosclerosis, which in turn results in coronary artery disease (CAD). Atherosclerosis is being considered as an inflammatory disease. Vaccinium arctostaphylos L. is a plant with fruits rich in anthocyanins. The aim of this study was to evaluate the effects of fruit extract of this plant on serum levels of lipids, hs-CRP, and malondialdehyde (MDA) as a marker of oxidative stress, in hyperlipidemic adult patients. Methods. In this randomized, double-blind, placebo-controlled clinical trial, 50 hyperlipidemic adult patients were randomly and equally assigned to receive either medicinal (V. arctostaphylos fruit extract) or placebo capsules twice daily for 4 weeks. Each medicinal capsule contained 45 ± 2 mg of anthocyanins. Fasting serum levels of total cholesterol, TG, LDL-C, HDL-C, hs-CRP, and MDA were obtained before and after the intervention and compared. Results. V. arctostaphylos fruit extract significantly reduced total cholesterol (P < 0.001), LDL-C (P = 0.004), TG (P < 0.001), and MDA (P = 0.013) compared to placebo but did not have any significant effect on HDL-C (P = 0.631) and hs-CRP (P = 0.190). Conclusion. Fruit extract of Vaccinium arctostaphylos has beneficial effects on serum lipid profile and oxidative stress in hyperlipidemic adult patients. Therefore, it could be considered as a supplement for treatment of dyslipidemia and prevention of atherosclerosis development. DOI: 10.1155/2014/217451 PMCID: PMC3920853 PMID: 24587807
4. Georgian Med News. 2006 Dec;(141):66-72. Effect of Blueberin on fasting glucose, C-reactive protein and plasma aminotransferases, in female volunteers with diabetes type 2: double-blind, placebo controlled clinical study. Abidov M(1), Ramazanov A, Jimenez Del Rio M, Chkhikvishvili I. Author information: (1)Institute of Immunopathology, Center of Modern Medicine, Russian Academy of Natural Sciences, Moscow, Russia. In a 4-week randomized placebo-controlled clinical trial we investigated the effect of 300 mg Blueberin, a phytomedicine containing 250 mg Blueberry leaves (Vaccinium arctostaphylos L, Ericaceae) extract providing minimum 50 mg 3,4-caffeoylquinic (chlorogenic) acid, and 50 mg myricetin, on fasting plasma glucose, alanine aminotransferases (ALT), aspartate aminotransferases (AST), glutamyltransferase (GGT) enzymes levels, and serum inflammatory C-Reactive proteins (CRP) in forty-two volunteer subjects (46+/-15 year of age, BMI 25+/-3 kgs/(m2)) diagnosed with Type 2 diabetes. During the 4-week trial, the Blueberin supplement was administered three times per day, 15-30 minutes prior to a meal along with 100 ml of water. Results of this trial revealed that the supplementation of Blueberin reduced fasting plasma glucose from 143+/-5,2mg/L to 104+/-5,7 mg/L (p<0,001), whereas there was no statistically significant changes in the Placebo group from 138+/-4,8 mg/L to 126+/-5,1mg/L (p>0,05). The reduction of fasting glucose was correlated with the reduction of serum CRP and in the Blueberin group from 5,18+/-1,4 mg/l to 2,14+/-1,8 mg/L (p<0,05), whereas in the Placebo group CRP levels were not significantly reduced from 5,11+/-1,7 mg/l to 4,94+/-1,1mg/L (p>0,05). Furthermore, the Blueberin also significantly reduced the levels of plasma enzymes ALT, AST and GGT, indicating that, in addition to anti-diabetes effects, the Blueberin also possess pharmacologically relevant anti-inflammatory properties. PMID: 17261891 [Indexed for MEDLINE]
5. BMJ Open. 2020 Oct 1;10(10):e035883. doi: 10.1136/bmjopen-2019-035883. Strategies to reduce antibiotic use in women with uncomplicated urinary tract infection in primary care: protocol of a systematic review and meta-analysis including individual patient data. Heinz J(#)(1), Röver C(#)(2), Furaijat G(3)(4), Kaußner Y(5), Hummers E(3), Debray T(6), Hay AD(7), Heytens S(8), Vik I(9)(10), Little P(11), Moore M(11), Stuart B(11), Wagenlehner F(12), Kronenberg A(13), Ferry S(14), Monsen T(14), Lindbaek M(9), Friede T(2), Gagyor I(5). Author information: (1)Department of Medical Statistics, University Medical Center Goettingen, Goettingen, Germany judith.heinz@med.uni-goettingen.de. (2)Department of Medical Statistics, University Medical Center Goettingen, Goettingen, Germany. (3)Department of General Practice, University Medical Center Goettingen, Goettingen, Germany. (4)Department of Emergency Medicine, University Medical Center Goettingen, Goettingen, Germany. (5)Department of General Practice, Julius Maximilians University Wuerzburg Faculty of Medicine, Wuerzburg, Germany. (6)Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. (7)Centre for Academic Primary Care, University of Bristol, Bristol, UK. (8)Department of Public Health and Primary Care, University of Ghent, Gent, Belgium. (9)Department of General Practice, The Antibiotic Centre of Primary Care, Institute of Health and Society, University of Oslo, Oslo, Norway. (10)Department of Emergency General Practice, Oslo Accident and Emergency Outpatient Clinic, Oslo, Norway. (11)Primary Care Population Sciences and Medical Education Unit, University of Southampton School of Medicine, Southampton, UK. (12)Clinic for Urology, Pediatric Urology and Andrology, Justus Liebig University Giessen Faculty of Medicine, Giessen, Germany. (13)Institute for Infectious Diseases, University of Bern, Bern, Switzerland. (14)Department of Clinical Microbiology, Bacteriology, Umea University, Umea, Sweden. (#)Contributed equally INTRODUCTION: Uncomplicated urinary tract infection (UTI) in women is a common reason to present in general practice and is usually treated with antibiotics to reduce symptom severity and duration. Results of recent clinical trials indicate that non-antibiotic treatment approaches can also be effective. However, it remains unclear which patients would benefit from antibiotic treatment and which can effectively and safely be treated without antibiotics. This systematic review and meta-analysis aims to estimate the effect of treatment strategies to reduce antibiotic use in comparison with immediate antibiotic treatment and to identify prognostic factors and moderators of treatment effects. A further aim is to identify subgroups of patients benefiting from a specific therapy. METHODS AND ANALYSIS: A systematic literature search will be performed to identify randomised controlled trials which investigated the effect of treatment strategies to reduce antibiotic use in female adults with uncomplicated UTI compared with immediate antibiotic treatment. Therefore, the primary outcome of the meta-analysis is incomplete recovery. Anonymised individual patient data (IPD) will be collected. Aggregate data will be used for pairwise comparisons of treatment strategies using meta-analysis models with random effects accounting for potential between-study heterogeneity. Potential effect moderators will be explored in meta-regressions. For IPD, generalised linear mixed models will be used, which may be adjusted for baseline characteristics. Interactions of baseline variables with treatment effects will be explored. These models will be used to assess direct comparisons of treatment, but might be extended to networks. ETHICS AND DISSEMINATION: The local institutional review and ethics board judged the project a secondary analysis of existing anonymous data which meet the criteria for waiver of ethics review. Dissemination of the results will be via published scientific papers and presentations. Key messages will be promoted for example, via social media or press releases. PROSPERO REGISTRATION NUMBER: CRD42019125804. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. DOI: 10.1136/bmjopen-2019-035883 PMCID: PMC7534728 PMID: 33004385 [Indexed for MEDLINE] Conflict of interest statement: Competing interests: IG, GF, TF, EH, MM are involved in the following studies: ‘REGATTA—reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi’. Afshar K, Fleischmann N, Schmiemann G, Bleidorn J, Hummers-Pradier E, Friede T, Wegscheider K, Moore M, Gagyor I. 'Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA)—a double-blind, randomised, controlled comparative effectiveness trial'. BMC Complement Altern Med. 2018 Jul 3;18(1):203. doi: 10.1186/s12906-018-2266-x). IV was involved in the study: ‘Vik I, Bollestad M, Grude N, Bærheim A, Damsgaard E, Neumark T, Bjerrum L, Cordoba G, Olsen IC, Lindbæk M. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—a double-blind, randomised non-inferiority trial'. PLoS Med 15;5:e1002569. Doi.org/10.1371/journal.pmed.1002569. MM, ADH and PL are coauthors of the study: ‘Moore M, Trill J, Simpson C, Webley F, Radford M, Stanton L, Maishman T, Glanopoulou A, Flower A, Eyles C, Willcox M, Hay AD, van der Werf E, Gibbons S, Lewith G, Little P, Griffiths G. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomised trial. Clinical Microbiology and Infection'. Doi.org/10.1016/j.cmi.2019.01.011. SH was involved in the study with the reference number 11. PL and MM were involved in the study with the reference number 12. SF and TM were involved in the study with the reference number 13. IG, EH were involved in the studies with the reference numbers 14 and 15. AK was involved in the study with the reference number 16.
6. J Diet Suppl. 2021;18(1):31-43. doi: 10.1080/19390211.2020.1727076. Epub 2020 Feb 21. Efficacy and Safety of a Traditional Herbal Combination in Patients with Type II Diabetes Mellitus: A Randomized Controlled Trial. Mehrzadi S(1), Mirzaei R(2), Heydari M(3), Sasani M(4), Yaqoobvand B(5), Huseini HF(5). Author information: (1)Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran. (2)Avesta Pharmed Hakim, Tehran, Iran. (3)Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. (4)Diabetic Clinic of Diabetic Society, Karaj, Iran. (5)Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran. BACKGROUND: Capparis spinosa, Rosa canina, Securidaca securigera, Silybum marianum, Urtica dioica, Trigonella foenum-graecum and Vaccinium arctostaphylos are used traditionally as an herbal combination for treatment of diabetic patients in Iran. Despite the clinical evidence supporting their use in solitary form, no controlled human study has determined the efficacy and safety of their combination in treatment of diabetic patients. METHODS: A total 150 type II diabetic patients of both sexes under the oral anti-hyperglycemic drugs treatment (maximum 10 mg glyburide and 1000 mg metformin daily) were randomly assigned to three groups. The patients in each group received either herbal combination or placebo or metformin capsule daily for three months, without any change in their previous oral anti-hyperglycemic drugs dosage. Herbal combination, placebo and metformin capsules matched by shape and color were prepared in the Institute of Medicinal Plants Karaj, Iran. To assess the efficacy and safety of the treatments, the patients fasting plasma glucose, HbA1c, lipid profile, liver enzymes and renal function were determined at the beginning of the study and after three months. RESULTS: Results showed that after three months, the fasting plasma glucose, HbA1c and cholesterol levels in herbal combination were decreased significantly as compared to placebo group (20% and 12% respectively) and also compared to base line (25% and 15% respectively). The herbal combination was as effective as metformin in reduction of FPG (p = 0.001, p = 0.001) and HbA1c (p = 0.028 and p = 0.050 respectively) compared to placebo. No notable hepatic, renal and gastrointestinal side effects were observed in the trial groups. CONCLUSION: The results suggest that traditional herbal combination may safely improve glycemic control in type II diabetic patients with no significant adverse effect. [Formula: see text]. DOI: 10.1080/19390211.2020.1727076 PMID: 32081056 [Indexed for MEDLINE]
7. Complement Ther Med. 2019 Jun;44:296-300. doi: 10.1016/j.ctim.2019.05.010. Epub 2019 May 8. Antihypertensive efficacy and safety of Vaccinium arctostaphylos berry extract in overweight/obese hypertensive patients: A randomized, double-blind and placebo-controlled clinical trial. Kianbakht S(1), Hashem-Dabaghian F(2). Author information: (1)Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran; Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran. Electronic address: skianbakht@yahoo.com. (2)Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran; School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran. OBJECTIVES: To evaluate the antihypertensive efficacy and safety of a standardized Vaccinium arctostaphylos (V. arctostaphylos) berry hydro-alcoholic extract in the overweight/obese hypertensive patients. DESIGN: Randomized placebo-controlled trial. SETTING: Baqiyatallah hospital (Tehran, Iran). INTERVENTIONS: The antihypertensive efficacy and safety of 3-month intake of 400 mg extract capsule three times daily alongside standardized anti-hypertensive regimen in the treatment of 50 patients was compared with the placebo (n = 50). MAIN OUTCOME MEASURES: SBP (systolic blood pressure), DBP (diastolic blood pressure), body mass index, waist circumference, CBC (complete blood count), blood levels of AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase), BUN (blood urea nitrogen) and creatinine. RESULTS: SBP decreased from 152.1 ± 7.7 to 140.5 ± 10.7 in the V. arctostaphylos group and from 152.9 ± 8.1 to 150.8 ± 9.3 in the placebo group (P < 0.001). DBP decreased from 90.3±8 to 82.1±8.8 in the V. arctostaphylos group and from 89.6 ± 7.8 to 87.6 ± 7.9 in the placebo group (P < 0.001). The extract capsule had no significant effect on the other parameters (P > 0.05). Moreover, no drug side effect and adverse interaction with other antihypertensive drugs was observed in the patients. CONCLUSIONS: V. arctostaphylosberry extract improves blood pressure control and has safety and tolerability in the overweight/obese hypertensive patients taking standard antihypertensive drugs. Copyright © 2019 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.ctim.2019.05.010 PMID: 31126570 [Indexed for MEDLINE]
8. Clin Microbiol Infect. 2019 Aug;25(8):973-980. doi: 10.1016/j.cmi.2019.01.011. Epub 2019 Jan 25. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Moore M(1), Trill J(2), Simpson C(3), Webley F(3), Radford M(3), Stanton L(3), Maishman T(3), Galanopoulou A(3), Flower A(2), Eyles C(2), Willcox M(2), Hay AD(4), van der Werf E(4), Gibbons S(5), Lewith G(2), Little P(2), Griffiths G(3). Author information: (1)Primary Care and Population Science, University of Southampton Faculty of Medicine, Aldermoor Health Centre, Southampton, UK. Electronic address: mvm198@soton.ac.uk. (2)Primary Care and Population Science, University of Southampton Faculty of Medicine, Aldermoor Health Centre, Southampton, UK. (3)Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton MP131, Southampton General Hospital, Tremona Road, Southampton, UK. (4)Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, UK. (5)Research Department of Pharmaceutical and Biological Chemistry UCL School of Pharmacy, London, UK. OBJECTIVES: The aim was to investigate if offering symptomatic therapy (Uva-ursi or ibuprofen) alongside a delayed prescription would relieve symptoms and reduce the consumption of antibiotics for adult women presenting with acute uncomplicated urinary tract infection (UTI). METHODS: A 2 × 2 factorial placebo controlled randomized trial in primary care. The participants were 382 women aged 18-70 years with symptoms of dysuria, urgency, or frequency of urination and suspected by a clinician to have a lower UTI. The interventions were Uva-ursi extract and/or ibuprofen advice. All women were provided with a delayed or 'back-up' prescription for antibiotics. Missing data were imputed using multiple imputation methods (ISRCTN registry: ISRCTN43397016). RESULTS: An ITT analysis of mean score for frequency symptoms assessed on Days 2-4 found no evidence of a difference between Uva-ursi vs. placebo -0.06 (95% CI -0.33 to 0.21; p 0.661), nor ibuprofen vs. no ibuprofen advice -0.01 (95% CI -0.27 to 0.26; p 0.951). There was no evidence of a reduction in antibiotic consumption with Uva-ursi (39.9% vs. placebo 47.4%; logistic regression odds ratio (OR) 0.59 (95% CI 0.22-1.58; p 0.293) but there was a significant reduction for ibuprofen advice (34.9% vs. no advice 51.0%; OR 0.27 (95% CI 0.10 to 0.72; p 0.009). There were no safety concerns and no episodes of upper tract infection were recorded. CONCLUSIONS: We found no evidence of an effect of either intervention on the severity of frequency symptoms. There is evidence that advice to take ibuprofen will reduce antibiotic consumption without increasing complications. For every seven women given this advice, one less will use antibiotics. Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. DOI: 10.1016/j.cmi.2019.01.011 PMID: 30685500 [Indexed for MEDLINE]
9. BMC Complement Altern Med. 2018 Jul 3;18(1):203. doi: 10.1186/s12906-018-2266-x. Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) - a double-blind, randomized, controlled comparative effectiveness trial. Afshar K(1), Fleischmann N(2), Schmiemann G(3), Bleidorn J(1), Hummers-Pradier E(2), Friede T(4), Wegscheider K(5), Moore M(6), Gágyor I(7). Author information: (1)Institute for General Practice, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. (2)Department of General Practice, University Medical Center Göttingen, Humboldtallee 38, 37073, Göttingen, Germany. (3)Department for Health Services Research, Institute for Public Health and Nursing Research, University of Bremen, Bremen, Germany. (4)Department of Medical Statistics, University Medical Center Göttingen, Humboldtallee 32, 37073, Göttingen, Germany. (5)Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr, 52, 20246, Hamburg, Germany. (6)Primary Care and Population Science, University of Southampton Faculty of Medicine, Aldermoor Health Centre, Southampton, SO16 5ST, UK. (7)Department of General Practice, Universitätsklinikum Wurzburg, Josef-Schneider-Str. 2/D7, 97080, Würzburg, Germany. gagyor_i@ukw.de. BACKGROUND: Uncomplicated urinary tract infections (UTI) are common in general practice and usually treated with antibiotics. This contributes to increasing resistance rates of uropathogenic bacteria. A previous trial showed a reduction of antibiotic use in women with UTI by initial symptomatic treatment with ibuprofen. However, this treatment strategy is not suitable for all women equally. Arctostaphylos uva-ursi (UU, bearberry extract arbutin) is a potential alternative treatment. This study aims at investigating whether an initial treatment with UU in women with UTI can reduce antibiotic use without significantly increasing the symptom burden or rate of complications. METHODS: This is a double-blind, randomized, and controlled comparative effectiveness trial. Women between 18 and 75 years with suspected UTI and at least two of the symptoms dysuria, urgency, frequency or lower abdominal pain will be assessed for eligibility in general practice and enrolled into the trial. Participants will receive either a defined daily dose of 3 × 2 arbutin 105 mg for 5 days (intervention) or fosfomycin 3 g once (control). Antibiotic therapy will be provided in the intervention group only if needed, i.e. for women with worsening or persistent symptoms. Two co-primary outcomes are the number of all antibiotic courses regardless of the medical indication from day 0-28, and the symptom burden, defined as a weighted sum of the daily total symptom scores from day 0-7. The trial result is considered positive if superiority of initial treatment with UU is demonstrated with reference to the co-primary outcome number of antibiotic courses and non-inferiority of initial treatment with UU with reference to the co-primary outcome symptom burden. DISCUSSION: The trial's aim is to investigate whether initial treatment with UU is a safe and effective alternative treatment strategy in women with UTI. In that case, the results might change the existing treatment strategy in general practice by promoting delayed prescription of antibiotics and a reduction of antibiotic use in primary care. TRIAL REGISTRATION: EudraCT: 2016-000477-21 . Clinical trials.gov: NCT03151603 (registered: 10 May 2017). DOI: 10.1186/s12906-018-2266-x PMCID: PMC6029138 PMID: 29970072 [Indexed for MEDLINE] Conflict of interest statement: ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Ethical approval has been obtained by the Independent Ethics Committees of the University Medical Center Göttingen (No. 16/11/16). Informed written consent will be obtained from all participants prior to any trial-related procedures. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors have no conflicts of interest to declare. Haupt Pharma Wulfing GmbH was contracted to produce and repack the trial medication (Arctuvan®). The company did not have influence on the study design and will participate neither in the clinical project management nor in the collection, analysis, and interpretation of data. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
10. Trials. 2017 Sep 8;18(1):421. doi: 10.1186/s13063-017-2145-7. Uva-ursi extract and ibuprofen as alternative treatments of adult female urinary tract infection (ATAFUTI): study protocol for a randomised controlled trial. Trill J(1), Simpson C(2), Webley F(2), Radford M(2), Stanton L(2), Maishman T(2), Galanopoulou A(2), Flower A(3), Eyles C(3), Willcox M(3), Hay A(4), Griffiths G(2), Little P(3), Lewith G(3), Moore M(3). Author information: (1)Primary Care and Population Science, University of Southampton Faculty of Medicine, Aldermoor Health Centre, Southampton, SO16 5ST, England. jldt1g12@soton.ac.uk. (2)Southampton Clinical Trials Unit, University of Southampton Clinical Trials Unit MP131, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, England. (3)Primary Care and Population Science, University of Southampton Faculty of Medicine, Aldermoor Health Centre, Southampton, SO16 5ST, England. (4)Centre for Academic Primary Care, National Institute for Health Research (NIHR) School for Primary Care Research, Population Health Sciences, Bristol Medical School, University of Bristol, Whatley Road, Bristol, BS8 2PS, England. BACKGROUND: Women with acute uncomplicated urine infection are usually treated with antibiotics. One trial has demonstrated that delayed antibiotic treatment offered without symptom relief results in a modest reduction in antibiotic use. There is some evidence that ibuprofen provides symptom relief and reduces antibiotic use. Uva-ursi, a herbal product, has a traditional use for urinary infection symptom relief. We set out to test: in adult women with suspected UTI who accept the delayed prescription strategy: Do NSAIDs or uva-ursi (a herbal product) provide relief from urinary symptoms and reduce antibiotic use. METHODS/DESIGN: Adult women with suspected urinary tract infection presenting to primary care will be randomised using a factorial trial design in which patients will be randomised to one of two interventions as below: Group 1 - Uva-ursi + advice to take ibuprofen Group 2 - Placebo + advice to take ibuprofen Group 3 - Uva-ursi + no advice to take ibuprofen Group 4 - Placebo + no advice to take ibuprofen Patients and physicians will be blinded to the randomised group for the herb. The main outcome is symptom severity at days 2-4 recorded in a validated, self-report diary used in previous studies. Secondary outcomes include antibiotic use and symptom duration. In total the trial will require 328 patients in order to achieve at least 90% power for the primary endpoint and 80% for the secondary endpoint. In accordance with CONSORT guidelines all comparative analyses will be conducted on an intention-to-treat basis using SPSS or similar package. DISCUSSION: The outcomes from this trial have the potential to modify the current approach to the management of acute urinary symptoms with less dependence on the use of antibiotics. TRIAL REGISTRATION: ISRCTN registry, ID: ISRCTN43397016 . Registered on 11 February 2015. DOI: 10.1186/s13063-017-2145-7 PMCID: PMC5591533 PMID: 28886751 [Indexed for MEDLINE] Conflict of interest statement: AUTHORS’ INFORMATION: Not applicable. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: In compliance with the Helsinki Declaration, the ATAFUTI trial has been granted ethical approval by the South Central – Hampshire Research Ethics Committee (REC, 14/SC/1143), and UK Medicines and Health Care Products Regulatory Agency (MHRA) (reference 16730/0215/001-0001). All ethical bodies involved in the recruiting and participating centres are listed in an additional file (see Additional file 12). Informed written consent will be obtained from all participants. CONSENT FOR PUBLICATION: Neither individual patient data nor identifiable information which could compromise the confidentiality of the study participants will be included. Informed written consent will be obtained for publication of the study. COMPETING INTERESTS: The authors declare that they have no competing interests. There are no limitations on access to the data set for the investigators. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
11. Forsch Komplementmed. 2013;20(1):17-22. doi: 10.1159/000346607. Epub 2013 Feb 19. Anti-hyperglycemic effect of Vaccinium arctostaphylos in type 2 diabetic patients: a randomized controlled trial. Kianbakht S(1), Abasi B, Dabaghian FH. Author information: (1)Research Institute for Islamic and Complementary Medicine, Tehran University of Medical Sciences, Tehran, Iran. skianbakht@yahoo.com BACKGROUND: Type 2 diabetes mellitus is a common disease. Preliminary data indicate that Vaccinium arctostaphylos L. (Caucasian whortleberry) has a potential effect in glycemic control. Thus, the efficacy and safety of a standardized whortleberry fruit hydroalcoholic extract in the treatment of type 2 diabetic patients were studied. METHODS: This randomized double-blind placebo-controlled clinical trial consisted of 37 patients aged 40-60 years with type 2 diabetes who were resistant to conventional oral anti-hyperglycemic drugs. The patients were treated with the whortleberry fruit hydroalcoholic extract (1 capsule = 350 mg, every 8 h for 2 months) in combination with anti-hyperglycemic drugs, and the effects on the blood levels of fasting glucose, 2-hour postprandial glucose, glycosylated hemoglobin (HbA1c), and liver/kidney function were tested, evaluated, and compared with a placebo group (n = 37). RESULTS: The extract significantly lowered the blood levels of fasting glucose, 2-h postprandial glucose, and HbA1c (p = 0.007, p <0.001, and p = 0.005, respectively) without any significant effects on the liver/kidney function (p >0.05) compared with placebo at the end. No adverse effects were reported. CONCLUSION: Whortleberry may safely improve glycemic control in type 2 diabetic patients. Copyright © 2013 S. Karger AG, Basel. DOI: 10.1159/000346607 PMID: 23727759 [Indexed for MEDLINE]
12. Phytother Res. 2014 Mar;28(3):432-6. doi: 10.1002/ptr.5011. Epub 2013 May 20. Improved lipid profile in hyperlipidemic patients taking Vaccinium arctostaphylos fruit hydroalcoholic extract: a randomized double-blind placebo-controlled clinical trial. Kianbakht S(1), Abasi B, Hashem Dabaghian F. Author information: (1)Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran; Department of Pharmacology and Applied Medicine, Research Institute of Medicinal Plants, ACECR, Karaj, Iran. Dyslipidemia is a common contributory cause of cardiovascular disease. Vaccinium arctostaphylos L. (Caucasian whortleberry) fruit is rich of anthocyanins. Anthocyanins may exert cardioprotective effects by various mechanisms such as favorably modulating dyslipidemia. Therefore, in this randomized double-blind placebo-controlled clinical trial with hyperlipidemic (hypercholesterolemic and/or hypertriglyceridemic) patients aged 20-60 years, the effects of taking a standardized whortleberry fruit hydroalcoholic extract (one 350 mg capsule every 8 h for 2 months) on fasting blood levels of lipids, creatinine and liver enzymes including SGOT and SGPT were evaluated in 40 patients and compared with the placebo group (n = 40). The extract lowered the blood levels of total cholesterol (P < 0.001), triglyceride (P = 0.002) and low-density lipoprotein cholesterol (LDL-C) (P = 0.002), but increased the blood high-density lipoprotein cholesterol (HDL-C) levels (P < 0.001) without any significant effects on the blood levels of SGOT, SGPT and creatinine (P > 0.05) compared with the placebo group at the endpoint. Whortleberry reduced total cholesterol, triglyceride and LDL-C 27.6%, 19.2% and 26.3%, respectively, but increased HDL-C 37.5% compared with baseline. No adverse effects were reported. Short-term treatment with whortleberry fruit appears safe and improves lipid profile in hyperlipidemic patients. Copyright © 2013 John Wiley & Sons, Ltd. DOI: 10.1002/ptr.5011 PMID: 23686894 [Indexed for MEDLINE]
13. J Clin Pharmacol. 2002 Aug;42(8):920-7. doi: 10.1177/009127002401102740. Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. Schindler G(1), Patzak U, Brinkhaus B, von Niecieck A, Wittig J, Krähmer N, Glöckl I, Veit M. Author information: (1)Friedrich-Alexander University, Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany. Bearberry leaves and preparations made from them are traditionally used for urinary tract infections. The urinary excretion of arbutin metabolites was examined in a randomized crossover design in 16 healthy volunteers after the application of a single oral dose of bearberry leaves dry extract (BLDE). There were two groups of application using either film-coated tablets (FCT) or aqueous solution (AS). The urine sample analysis was performed by a validated HPLC coolarray method (hydroquinone) and a validated capillary electrophoresis method (hydroquinone-glucuronide, hydroquinone-sulfate). The total amounts of hydroquinone equivalents excreted in the urine from BLDE were similar in both groups. With FCT, 64.8% of the arbutin dose administered was excreted; with AS, 66.7% was excreted (p = 0.61). The maximum mean urinary concentration of hydroquinone equivalents was a little higher and peaked earlier in the AS group versus the FCT group, although this did not reach statistical significance (Cur max = 1.6893 micromol/ml vs. 1.1250 micromol/ml, p = 0.13; tmax (t midpoint) = 3.60 h vs. 4.40 h, p = 0.38). The relative bioavailability of FCT compared to AS was 103.3% for total hydroquinone equivalents. There was substantial intersubject variability. No significant differences between the two groups were found in the metabolite patterns detected (hydroquinone, hydroquinone-glucuronide, and hydroquinone-sulfate). DOI: 10.1177/009127002401102740 PMID: 12162475 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.